Robert K Mccowan, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 66707 Gratiot Ave, Lenox, MI 48050 Phone: 586-727-5840 Fax: 586-727-5897 |
Pietro Cavataio, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 36267 26 Mile Road, Suite 3, Lenox, MI 48048 Phone: 586-716-1371 Fax: 586-716-4855 |
Dr. Heather M Plumer-haun, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 66707 Gratiot Ave, Lenox, MI 48050 Phone: 586-727-5840 Fax: 586-727-5897 |
Dr. Christopher J Frocillo, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 66707 Gratiot Ave, Lenox, MI 48050 Phone: 586-727-5840 Fax: 586-727-5897 |
Antonino G Colombo, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 36267 26 Mile Road, Suite 3, Lenox, MI 48048 Phone: 586-716-1371 Fax: 586-716-4855 |
News Archive
TYRX, Inc. announced today that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker or implantable cardioverter defibrillator in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
The U.S. "ranks among the lowest in terms of the quality and effectiveness of its aid," according to a new Center for Global Development/Brookings Institution report, Foreign Policy's "The Cable" blog writes.
Flasks, beakers and hot plates may soon be a thing of the past in chemistry labs. Instead of handling a few experiments on a bench top, scientists may simply pop a microchip into a computer and instantly run thousands of chemical reactions, with results - literally shrinking the lab down to the size of a thumbnail.
Vaccines are an important part of routine healthcare for adults, seniors and women who are pregnant.
YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.
› Verified 9 days ago